Nautilus Biotechnology, Inc. (NAUT)
| Market Cap | 303.15M +80.5% |
| Revenue (ttm) | 424,000 |
| Net Income | -58.58M |
| EPS | -0.46 |
| Shares Out | 127.37M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,887,009 |
| Open | 2.400 |
| Previous Close | 2.335 |
| Day's Range | 2.315 - 2.550 |
| 52-Week Range | 0.841 - 4.310 |
| Beta | 0.73 |
| Analysts | Strong Buy |
| Price Target | 4.00 (+68.07%) |
| Earnings Date | Oct 27, 2026 |
About NAUT
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States. The company develops Nautilus Voyager Platform, which includes an end-to-end solution comprising instruments, reagents, consumables, and software analysis. It also provides nautilus voyager instrument, a high-resolution optical imaging system with integrated fluidics and liquid handling sub-system to deposit protein libraries onto a flow cell and to ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for NAUT stock is "Strong Buy." The 12-month stock price target is $4.0, which is an increase of 68.07% from the latest price.
News
Nautilus Biotechnology price target raised to $4 from $3.50 at Roth Capital
Roth Capital raised the firm’s price target on Nautilus Biotechnology (NAUT) to $4 from $3.50 and keeps a Buy rating on the shares. The company’s Q3 update strengthened the firm’s…
Nautilus Biotechnology Earnings Call Transcript: Q3 2026
Q3 revenue was $200,000 and net loss was $15.6M; cash runway is projected into Q1 2028. The roadmap targets Voyager pre-orders in early 2027, shipments in mid-2027, and 20 assays by mid-2028.
Nautilus Biotechnology Earnings release: Q3 2026
Nautilus Biotechnology released its Q3 2026 earnings on October 27, 2026, summarizing the period's financial results.
Nautilus Biotechnology Quarterly report: Q3 2026
Nautilus Biotechnology has published its Q3 2026 quarterly earnings report on October 27, 2026.
Nautilus Biotechnology reports Q3 EPS (12c) vs. (11c) last year
Reports Q3 revenue $200K, consensus $206.25K. Cash, cash equivalents, and investments were $114.3M as of September 30, 2026. “Q3 marked an important step in demonstrating the power and scalability of…
Nautilus to Measure Proteoforms Driving Alzheimer's Disease and Cancer in ARPA-H-Funded SEEDS Consortium
Nautilus expects to receive up to $6 million to bring its Voyager™ Platform to a multidisciplinary team integrating protein science, AI, and computational modeling to develop new diagnostics and thera...
Nautilus Biotechnology Reports Third Quarter 2026 Financial Results
SEATTLE, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the thir...
Nautilus Biotechnology to Announce Third Quarter 2026 Financial Results on October 27, 2026
SEATTLE, Oct. 15, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology initiated with a Buy at Roth Capital
Roth Capital analyst Max Masucci initiated coverage of Nautilus Biotechnology (NAUT) with a Buy rating and $3.50 price target The company is developing a AI powered proteomics platform that resolves…
Nautilus Biotechnology files $300M mixed securities shelf
16:07 EDT Nautilus Biotechnology (NAUT) files $300M mixed securities shelf
Nautilus Biotechnology Registration statement: Registration filing
Nautilus Biotechnology filed a registration statement on September 11, 2026, providing details about a securities offering with the SEC.
Nautilus Biotechnology initiated with an Outperform at Leerink
Leerink initiated coverage of Nautilus Biotechnology (NAUT) with an Outperform rating and $4 price target
Nature Methods Publication Reveals Deep Insights into Functional Biology through First-of-its-Kind Quantification of Tau Proteoforms
First large-scale, single-molecule analysis of the tau proteoform landscape reveals unique disease-associated modifications, a new source of potential biomarkers and drug targets, and a method Nautilu...
Nautilus Biotechnology Earnings Call Transcript: Q2 2026
R&D focus has shifted to proteoform applications due to strong customer demand and technical progress, with first revenue recognized this quarter. Operating expenses declined, cash runway extends into 2028, and commercial ramp is expected as new assays and platform launches approach.
Nautilus Biotechnology Earnings release: Q2 2026
Nautilus Biotechnology released its Q2 2026 earnings on July 28, 2026, summarizing the period's financial results.
Nautilus Biotechnology Quarterly report: Q2 2026
Nautilus Biotechnology has published its Q2 2026 quarterly earnings report on July 28, 2026.
Nautilus Biotechnology Reports Second Quarter 2026 Financial Results
SEATTLE, July 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the seco...
Nautilus Biotechnology to Announce Second Quarter 2026 Financial Results on July 28, 2026
SEATTLE, July 08, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report ...
Nautilus Biotechnology Transcript: AGM 2026
The meeting covered director elections, auditor ratification, and advisory votes on executive compensation and its frequency. All proposals passed, with annual Say on Pay votes approved. No questions were submitted during the Q&A session.
Nautilus Biotechnology Earnings Call Transcript: Q1 2026
Q1 2026 saw strong execution on commercialization plans, reduced operating expenses, and expanded early access engagement, with Baylor College of Medicine as a key customer. Cash runway extends through 2027, and oncology assay development is on track for later this year.
Nautilus Biotechnology Earnings release: Q1 2026
Nautilus Biotechnology released its Q1 2026 earnings on April 28, 2026, summarizing the period's financial results.
Nautilus Biotechnology Quarterly report: Q1 2026
Nautilus Biotechnology has published its Q1 2026 quarterly earnings report on April 28, 2026.
Nautilus Biotechnology Reports First Quarter 2026 Financial Results
SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fir...
Nautilus Biotechnology Proxy statement: Proxy filing
Nautilus Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.
Nautilus Biotechnology Proxy statement: Proxy filing
Nautilus Biotechnology filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.